These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11428987)

  • 1. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy.
    Boeckh M
    Transpl Infect Dis; 1999 Sep; 1(3):165-78. PubMed ID: 11428987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.
    Boeckh M; Nichols WG; Papanicolaou G; Rubin R; Wingard JR; Zaia J
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):543-58. PubMed ID: 14506657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of cytomegalovirus infection in organ transplant recipients.
    Kusne S; Shapiro R; Fung J
    Transpl Infect Dis; 1999 Sep; 1(3):187-203. PubMed ID: 11428989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
    Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy.
    Koehler M; St George K; Ehrlich GD; Mirro J; Neudorf SM; Rinaldo C
    J Pediatr Hematol Oncol; 1997; 19(1):43-7. PubMed ID: 9065718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review.
    Jerry Teng CL; Wang PN; Chen YC; Ko BS
    J Microbiol Immunol Infect; 2021 Jun; 54(3):341-348. PubMed ID: 33514495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy?
    Abecassis MM; Koffron AJ; Kaplan B; Buckingham M; Muldoon JP; Cribbins AJ; Kaufman DB; Fryer JP; Stuart J; Stuart FP
    Transplantation; 1997 Jan; 63(2):275-9. PubMed ID: 9020330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
    Jaing TH; Chang TY; Chen SH; Wen YC; Yu TJ; Lee CF; Yang CP; Tsay PK
    Medicine (Baltimore); 2019 Jan; 98(4):e14172. PubMed ID: 30681583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
    Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
    Li L; Wang Y; Yan CH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2018 Mar; 57(3):191-195. PubMed ID: 29518863
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
    Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
    J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.